Clinical Trial Update: Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST) [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of Tasigna (nilotinib) for gastrointestinal stromal tumor has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Gastrointestinal Cancer | Phase 2 | Status: WITHDRAWN